Thermo Fisher Scientific Debt Issuance Proceeds increased by 6.5% to $5.24B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 84.4%, from $2.84B to $5.24B.
An increase indicates successful access to capital markets for expansion or refinancing, while a decrease may suggest a focus on deleveraging or limited market access.
This metric tracks the total cash proceeds received from the issuance of long-term or short-term debt instruments. It re...
Large-cap companies frequently issue debt to optimize their cost of capital; peers monitor this to maintain investment-grade credit ratings.
debt_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $3.12B | $15.02B | $3.19B | $0.00 | $0.00 | $3.47B | $2.48B | $1.21B | $2.84B | $4.92B | $5.24B |
| QoQ Change | — | — | +380.9% | -78.7% | -100.0% | — | — | -28.6% | -51.3% | +135.7% | +73.2% | +6.5% |
| YoY Change | — | — | — | -78.7% | — | — | — | -22.5% | — | +135.7% | — | +84.4% |